#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cutaneous calcification Glomerulonephritis acute Neonatal asphyxia Guillain-Barre syndrome Thrombocytosis Infection in an immunocompromised host Fragile X syndrome Endometrial adenocarcinoma Chronic myeloid leukaemia Autoimmune demyelinating disease B-cell type acute leukaemia Hyperadrenocorticism Primitive neuroectodermal tumour Anaemia Bronchopulmonary dysplasia More trials…

    Learn about Rare Diseases

    Antithrombin III deficiency – Life with Disease Stevens-Johnson syndrome Rhabdomyosarcoma Brain stem glioma – Treatment Haemophilia – Diagnostics Chondrosarcoma – Basic Information Hereditary optic atrophy – Life with Disease Langerhans’ cell histiocytosis – Life with Disease Small intestine leiomyosarcoma Adrenogenital syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mometasone Furoate Coffee Charcoal Benztropine Mesylate Mps-214 Tezacaftor Xtmab-16 GS-248 CHLORMADINONE ACETATE ZODASIRAN Bi 1839100 COBALAMIN 177LU-PSMA-I&T Soft Paraffin And Fat Products Mebeverine Hydrochloride Envudeucitinib Vorasidenib Zimberelimab Messenger Rna Encoding Cas9 Mbs2320 204-NETU More therapies…

    Learn about Your Condition

    Noninfective chorioretinitis Polycystic liver disease Chronic hepatitis B Oesophageal food impaction Eczema Cerebral haemorrhage Arterial tortuosity syndrome Peritoneal abscess Oesophageal cancer metastatic Bone metabolism disorder Cytomegalovirus infection HER2 positive gastric cancer Hip fracture Diabetic retinal oedema Exposure via breast milk More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Crohn’s disease

  • Study of mirikizumab and tirzepatide for adults with moderate to severe Crohn’s disease who are overweight or obese

    Recruiting

    3 1
    Investigated Drugs:
    • Mirikizumab
    • Tirzepatide
    Austria Belgium Bulgaria Czechia Denmark France +9

  • A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Risankizumab
    • Guselkumab
    Austria Belgium Czechia Denmark France Germany +7

  • A study of mirikizumab levels in breast milk of breastfeeding women with ulcerative colitis or Crohn’s disease

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Mirikizumab
    Denmark Germany Italy Poland Spain

  • One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    France

  • An observational study on the use of methotrexate in children and adolescents with Crohn’s disease

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Methotrexate
    The Netherlands

  • Using 68Ga-FAPI-46 imaging to detect fibrosis in patients with inflammatory diseases such as Crohn’s disease, ulcerative colitis, systemic sclerosis, and lung fibrosis.

    Recruiting

    2 1 1
    Investigated Diseases:
    • Idiopathic inflammatory myopathy
    • Interstitial lung disease
    • Systemic scleroderma
    Investigated Drugs:
    • (S)-2,2′,2”-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate
    The Netherlands
1 2 3 … 16
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!